Pfizer’s 6.58% yield contrasts with Merck’s 2.74%, as KEYTRUDA drives 12% revenue growth amid biosimilar risks.
Pfizer reported a 6.58% dividend yield for 2025, distributing $9.8 billion at $1.72 per share, supported by $3.22 adjusted EPS. Non-COVID growth surged, with Abrysvo up 136% and oncology biosimilars rising 77%.
Merck’s smaller 2.74% yield reflects faster underlying growth, led by KEYTRUDA’s $8.03 billion in Q1 2026 revenue, up 12%. WINREVAIR jumped 88% to $525 million, while Animal Health grew 13%. A dividend increase from $0.81 to $0.85 signals confidence.
The divergence highlights Pfizer’s focus on income stability versus Merck’s growth-driven returns, with KEYTRUDA’s patent cliff looming in 2027.